Entact Bio

Executive Summary

Entact Bio is a private biotechnology company based in Cambridge, MA, pioneering a novel class of small molecule therapies called ENTACs (Enhancers of Targeted Protein Abundance). Founded in 2021, the company's platform leverages molecular glues to recruit deubiquitylase (DUB) enzymes to specific target proteins, enhancing their function rather than inhibiting them. This approach addresses diseases driven by protein loss or dysfunction, initially focusing on oncology and immunology. By moving beyond traditional inhibition, Entact aims to unlock new therapeutic opportunities for conditions where protein enhancement is needed. The company is led by a team experienced in targeted protein degradation and small molecule drug discovery. While still in preclinical stages, Entact has secured early venture funding and is advancing its lead programs toward IND-enabling studies. The platform's potential for oral bioavailability and selectivity positions it as a promising player in the emerging field of targeted protein stabilization.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Financing Announcement75% success
• H2 2027Lead Program IND Filing40% success
• Q4 2026Preclinical Proof-of-Concept Data Publication60% success